Literature DB >> 3325936

Treatment of chronic postsurgical osteomyelitis with ciprofloxacin.

J A Hoogkamp-Korstanje1.   

Abstract

Sixteen patients (11F, 5M, age 18-83, mean 59.8 years) with chronic postsurgical osteomyelitis were treated with ciprofloxacin. The dosage was 500 or 750 mg twice daily orally during one to six months; four patients started with 300 mg twice daily intravenously and changed after 3-7 days to oral therapy. Twelve patients had implanted prostheses. The organisms involved were Enterobacteriaceae (11), Pseudomonas aeruginosa (7), Staphylococcus aureus (5), Streptococcus faecalis (4) and Bacteroides fragilis (1). Nine patients had pure cultures, seven mixed cultures. Cure (disappearance of infection symptoms, return of normal function with negative cultures, without resurgery) was obtained in 11 patients, improvement (resurgery required to obtain complete cure) in two. Three patients with infections by Staphylococcus aureus (2) and Pseudomonas aeruginosa (1) failed to respond after one and four months treatment respectively. No side effects were observed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3325936     DOI: 10.1007/bf02075271

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  6 in total

Review 1.  Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects.

Authors:  F A Waldvogel; G Medoff; M N Swartz
Journal:  N Engl J Med       Date:  1970-01-22       Impact factor: 91.245

2.  The treatment of bone infections with ceftazidime.

Authors:  J P Dutoy; G Wauters
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

3.  Clinical experience with cefotaxime in the treatment of serious bone and joint infections.

Authors:  J L LeFrock; B B Carr
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

4.  Oral ciprofloxacin therapy for chronic contiguous osteomyelitis caused by aerobic gram-negative bacilli.

Authors:  D N Gilbert; A D Tice; P K Marsh; P C Craven; L C Preheim
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

5.  Randomized trial of ciprofloxacin compared with other antimicrobial therapy in the treatment of osteomyelitis.

Authors:  R N Greenberg; A D Tice; P K Marsh; P C Craven; P M Reilly; M Bollinger; W J Weinandt
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

6.  Clinical efficacy of ciprofloxacin therapy for gram-negative bacillary osteomyelitis.

Authors:  M T Hessen; M J Ingerman; D H Kaufman; P Weiner; J Santoro; O M Korzeniowski; J Boscia; M Topiel; L M Bush; D Kaye
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

  6 in total
  3 in total

1.  Physiologically Based Population Pharmacokinetic Modeling Approach for Ciprofloxacin in Bone of Patients Undergoing Orthopedic Surgery.

Authors:  Cornelia B Landersdorfer; Martina Kinzig; Rainer Höhl; Peter Kempf; Roger L Nation; Fritz Sörgel
Journal:  ACS Pharmacol Transl Sci       Date:  2020-05-25

2.  Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.

Authors:  Cornelia B Landersdorfer; Martina Kinzig; Friedrich F Hennig; Jürgen B Bulitta; Ulrike Holzgrabe; George L Drusano; Fritz Sörgel; Johannes Gusinde
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

Review 3.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.